中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

声脉冲辐射力成像技术测量的肝脏硬度对肝硬化门静脉高压的诊断价值

王曦旋 丁量子 程洋 韩浩 杨建 肖江强 王轶 张明 张峰 诸葛宇征

引用本文:
Citation:

声脉冲辐射力成像技术测量的肝脏硬度对肝硬化门静脉高压的诊断价值

DOI: 10.3969/j.issn.1001-5256.2022.11.010
基金项目: 

国家自然科学基金 81900552

伦理学声明:本研究方案于2019年12月25日经由南京大学医学院附属鼓楼医院伦理委员会审批,批号:2019-265-01,所纳入患者均签署知情同意书。
利益冲突声明:本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。
作者贡献声明:王曦旋、程洋、丁量子负责数据收集;张峰、张明、肖江强、王轶、韩浩、杨建提供相关技术支持;王曦旋进行数据整理、统计学分析并撰写论文;诸葛宇征、张峰负责文章的构思与设计,指导撰写文章并最后定稿。
详细信息
    通信作者:

    张峰,fzdndx@126.com

    诸葛宇征,yuzheng9111963@aliyun.com

Value of liver stiffness measured by acoustic radiation force impulse in diagnosis of cirrhotic portal hypertension

Research funding: 

National Natural Science Foundation of China 81900552

More Information
  • 摘要:   目的  评估肝脏硬度(LS)无创预测失代偿期肝硬化患者肝静脉压力梯度(HVPG)的准确性,探讨LS对失代偿期肝硬化的诊断价值。  方法  回顾性分析2013年4月—2021年6月于南京鼓楼医院消化内科同时接受HVPG测定及声脉冲辐射力成像技术(ARFI)测定LS的88例病毒性肝炎肝硬化失代偿期或酒精性肝硬化失代偿期患者的临床资料,根据HVPG值将患者分为严重门静脉高压(SPH)组(HVPG≥20 mmHg,n=24)和非SPH组(HVPG<20 mmHg,n=64),比较两组间LS、脾脏硬度、门静脉流速及相关生化指标差异。计量资料两组间比较采用t检验或Mann-Whitney U秩和检验;计数资料两组间比较采用χ2检验。不同无创指标与HVPG的相关性采用Pearson相关分析。采用Logistic回归分析不同无创检测指标与SPH发生风险之间的关系。绘制不同无创指标预测HVPG≥20 mmHg发生的受试者工作特征曲线并计算曲线下面积(AUC)、敏感度、特异度、最大约登指数及对应的临界值,以评估各指标对SPH的预测价值。  结果  88例患者中病毒性肝炎相关肝硬化失代偿期76例,酒精性肝硬化失代偿期12例。SPH组与非SPH组患者的年龄、性别、白细胞计数、血红蛋白、血小板计数、凝血酶原时间、谷丙转氨酶、谷草转氨酶、白蛋白、血钠、肌酐、Child-Pugh肝功能分级、脾脏硬度等比较,差异均无统计学意义(P值均>0.05);两组间LS比较差异有统计学意义(t=-3.970,P<0.01)。相关分析结果显示HVPG与LS呈正相关(r=0.458,P<0.001)。Logistic回归分析结果显示,LS为SPH发生的危险因素(OR=3.941,95%CI:1.245~12.476,P=0.020)。受试者工作特征曲线结果显示,LS预测SPH发生的AUC为0.751,最佳临界值为2.295 m/s,敏感度为54.17%,特异度为90.63%。  结论  在失代偿期肝硬化患者中,ARFI测得的LS与HVPG相关,对肝硬化失代偿期HVPG≥20 mmHg的无创诊断具有一定价值。

     

  • 图  1  不同无创指标预测SPH发生风险的ROC曲线

    Figure  1.  ROC curve of different non-invasive index to predict the risk of SPH

    表  1  受试者基线资料

    Table  1.   Baseline of the patients included

    指标 所有患者(n=88) 非SPH组(n=64) SPH组(n=24) 统计值 P
    男/女(例) 65/23 48/16 17/7 χ2=0.157 0.79
    年龄(岁) 53.93±11.39 54.35±12.08 53.54±9.68 t=0.132 0.90
    病因(病毒性/酒精性,例) 76/12 56/8 20/4 χ2=0.257 0.73
    肝右叶斜径(cm) 12.20±1.48 12.56±1.28 12.57±1.66 t=-1.245 0.22
    内镜下静脉曲张程度(轻/中/重,例) 4/19/65 3/14/47 1/5/18 χ2=0.025 0.99
    白细胞计数(×109/L) 2.25(1.70~3.30) 1.90(1.55~3.30) 2.50(2.05~3.20) Z=-1.918 0.06
    血红蛋白(g/L) 86.64±26.66 82.35±25.97 86.64±26.66 t=0.124 0.90
    血小板计数(×109/L) 59.49±33.65 60.10±28.95 57.35±30.83 t=0.367 0.72
    凝血酶原时间(s) 14.89±2.74 14.35±1.64 15.90±3.10 t=-1.772 0.08
    国际标准化比值 1.31±0.20 1.25±0.15 1.39±0.26 t=-1.525 0.07
    谷丙转氨酶(U/L) 22.75(16.40~29.40) 24.75(15.90~29.00) 18.75(15.85~29.40) Z=-0.932 0.35
    谷草转氨酶(U/L) 26.75(21.25~35.55) 26.80(22.35~36.25) 23.15(20.10~31.50) Z=-1.466 0.14
    总胆红素(μmol/L) 16.90(11.00~22.35) 15.85(10.10~20.10) 18.70(13.10~31.70) Z=-1.743 0.08
    白蛋白(g/L) 35.43±4.77 36.43±4.45 33.96±5.31 t=1.155 0.25
    血肌酐(μmol/L) 67.14±19.23 64.15±14.74 64.29±21.46 t=0.787 0.43
    血钠(mmol/L) 141.20±2.60 141.16±3.13 141.23±2.84 t=-0.137 0.89
    腹水(有/无,例) 30/58 25/39 5/19 χ2=2.581 0.13
    Child-Pugh评分 6.85±1.32 6.40±1.05 7.25±1.29 t=-1.982 0.05
    Child-Pugh分级(A/B/C,例) 37/48/3 31/32/1 6/16/2 χ2=5.517 0.06
    下载: 导出CSV

    表  2  SPH组和非SPH组不同无创测定指标的比较

    Table  2.   The comparison of different noninvasive indexes between SPH group and non-SPH group

    指标 所有患者(n=88) 非SPH组(n=64) SPH组(n=24) t P
    LS(m/s) 2.00±0.43 1.88±0.34 2.33±0.50 -3.970 <0.01
    SS(m/s) 3.48±0.53 3.46±0.56 3.54±0.46 -0.612 0.54
    PVF(m/s) 27.56±9.53 27.65±9.59 27.33±9.58 0.139 0.89
    SVD(cm) 1.19±0.30 1.18±0.30 1.22±0.30 -0.430 0.67
    下载: 导出CSV

    表  3  SPH发生风险的Logistic回归分析

    Table  3.   Logistic regression analysis of SPH risk

    无创指标 OR 95%CI P
    LS 3.941 1.245~12.476 0.020
    SS 0.840 0.281~2.507 0.754
    PVF 0.542 0.192~1.527 0.246
    SVD 1.452 0.497~4.241 0.496
    Child-Pugh分级
      B级 0.184 0.011~3.192 0.245
      C级 0.402 0.027~5.948 0.507
    注:LS≤1.925 m/s赋值为0,LS>1.925 m/s赋值为1;SS≤3.50 m/s赋值为0,SS>3.50 m/s赋值为1;PVF≤25.85 m/s赋值为0,PVF>25.85 m/s赋值为1;SVD≤1.12 cm赋值为0,SVD>1.12 cm赋值为1;Child-Pugh分级以Child-Pugh A级为参考。
    下载: 导出CSV
  • [1] IWAKIRI Y, TREBICKA J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy[J]. JHEP Rep, 2021, 3(4): 100316. DOI: 10.1016/j.jhepr.2021.100316.
    [2] de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
    [3] GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906.
    [4] LEE E, KIM YJ, GOO DE, et al. Comparison of hepatic venous pressure gradient and endoscopic grading of esophageal varices[J]. World J Gastroenterol, 2016, 22(11): 3212-3219. DOI: 10.3748/wjg.v22.i11.3212.
    [5] ELKRIEF L, RONOT M, ANDRADE F, et al. Non-invasive evaluation of portal hypertension using shear-wave elastography: analysis of two algorithms combining liver and spleen stiffness in 191 patients with cirrhosis[J]. Aliment Pharmacol Ther, 2018, 47(5): 621-630. DOI: 10.1111/apt.14488.
    [6] DING NS, NGUYEN T, ISER DM, et al. Liver stiffness plus platelet count can be used to exclude high-risk oesophageal varices[J]. Liver Int, 2016, 36(2): 240-245. DOI: 10.1111/liv.12916.
    [7] KIM TY, JEONG WK, SOHN JH, et al. Evaluation of portal hypertension by real-time shear wave elastography in cirrhotic patients[J]. Liver Int, 2015, 35(11): 2416-2424. DOI: 10.1111/liv.12846.
    [8] FLEMING KM, AITHAL GP, CARD TR, et al. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study[J]. Aliment Pharmacol Ther, 2010, 32(11-12): 1343-1350. DOI: 10.1111/j.1365-2036.2010.04473.x.
    [9] LURIE Y, WEBB M, CYTTER-KUINT R, et al. Non-invasive diagnosis of liver fibrosis and cirrhosis[J]. World J Gastroenterol, 2015, 21(41): 11567-11583. DOI: 10.3748/wjg.v21.i41.11567.
    [10] KENNEDY P, WAGNER M, CASTÉRA L, et al. Quantitative elastography methods in liver disease: current evidence and future directions[J]. Radiology, 2018, 286(3): 738-763. DOI: 10.1148/radiol.2018170601.
    [11] CORPECHOT C, GAOUAR F, EL NAGGAR A, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis[J]. Gastroenterology, 2014, 146(4): 970-979. DOI: 10.1053/j.gastro.2013.12.030.
    [12] SINGH S, FUJⅡ LL, MURAD MH, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2013, 11(12): 1573-1584. DOI: 10.1016/j.cgh.2013.07.034.
    [13] BERZIGOTTI A, SEIJO S, ARENA U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis[J]. Gastroenterology, 2013, 144(1): 102-111. DOI: 10.1053/j.gastro.2012.10.001.
    [14] ABRALDES JG, BUREAU C, STEFANESCU H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study[J]. Hepatology, 2016, 64(6): 2173-2184. DOI: 10.1002/hep.28824.
    [15] XIE Q, LI Z, TANG Z, et al. Value of liver/spleen stiffness combined with serum adenosine deaminase in predicting severe esophageal varices in patients with hepatitis B cirrhosis[J]. J Clin Hepatol, 2021, 37(6): 1314-1318. DOI: 10.3969/j.issn.1001-5256.2021.06.020.

    谢青, 李曾, 唐臻, 等. 肝脾硬度联合血清腺苷脱氨酶对乙型肝炎肝硬化重度食管静脉曲张的预测价值分析[J]. 临床肝胆病杂志, 2021, 37(6): 1314-1318. DOI: 10.3969/j.issn.1001-5256.2021.06.020.
    [16] COSGROVE D, PISCAGLIA F, BAMBER J, et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 2: Clinical applications[J]. Ultraschall Med, 2013, 34(3): 238-253. DOI: 10.1055/s-0033-1335375.
    [17] D'ONOFRIO M, CROSARA S, de ROBERTIS R, et al. Acoustic radiation force impulse of the liver[J]. World J Gastroenterol, 2013, 19(30): 4841-4849. DOI: 10.3748/wjg.v19.i30.4841.
    [18] GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906.
    [19] MIAO CC, ZHUGE YZ, ZHANG M, et al. Correlation analysis between liver and spleen stiffness measured by acoustic radiation force impulse and hepatic venous pressure gradient[J]. Chin J Dig, 2017, 37(1): 30-34. DOI: 10.3760/cma.j.issn.0254-1432.2017.01.009.

    缪成成, 诸葛宇征, 张明, 等. 声脉冲辐射力成像测量的肝脏和脾脏硬度与肝静脉压力梯度的相关性分析[J]. 中华消化杂志, 2017, 37(1): 30-34. DOI: 10.3760/cma.j.issn.0254-1432.2017.01.009.
  • 加载中
图(1) / 表(3)
计量
  • 文章访问数:  105
  • HTML全文浏览量:  35
  • PDF下载量:  21
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-04-07
  • 录用日期:  2022-05-16
  • 出版日期:  2022-11-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回